"AstraZeneca plans major $3.5bn expansion drive in the US" was originally created and published by Investment Monitor, a ...

The boosted U.S. investment is said to be a response to Donald Trump’s election win, and leaves in doubt the pharmaceutical ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

The jobs include roles in engineering and technical services and global supply chain functions. Read more at straitstimes.com ...

AstraZeneca today announces $3.5 billion of capital investment ... the relationship that exists between a patient/site ...

Stay in the know with a recap of our top stories today. 1. AstraZeneca to open new $2b facility in Tuas by 2029, promises 800 ...

At about 23 hectares, the site will mark AstraZeneca’s largest to date in terms of initial build investment. It is targeted to be operationally ready by 2029 to produce antibody drug conjugates (ADCs) ...

Among the companies with reports and trading updates today are Metro Bank, AstraZeneca, BAE Systems, Vodafone and Drax.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

In 2023 Cullgen completed a Series C financing led by AstraZeneca-CICC Venture Capital Partnership, and also announced a strategic partnership with Astellas Pharma Inc.

AstraZeneca is building a US$1.5 billion manufacturing facility in Tuas South, Singapore, which will create over 800 jobs.